A Percutaneous Ultrasound Device With Needle Guide for Vascular Access
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Sept 2026
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- Vu-Path™
- Record updated
- 16 October 2025
- Why it stopped
- Expired IRB status
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Male or female participants, 18 years of age or older at the time of enrollment
- Participants meeting all medical conditions for percutaneous angiography
- International Normalized Ratio (INR) <1.3
- Written informed consent to participate in the study
- Ability to comply with the requirements of the study procedures
Who cannot take part
- Use of antithrombotic medication
- Active skin infection at the point of needle insertion
- Hemophilia, thrombocytopenia, coagulopathy, or other elevated risk for bleeding or abnormal clotting
- Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder, or any chronic condition that could, in the opinion of the investigator, of interfering with the conduct of the study
- For participants taking warfarin or other anticoagulant medication, INR >1.3
- Participants with the following laboratory values, unless approved by hematologist: Platelet count <100,000/mL, Activated Partial Thromboplastin Time (APTT) >39 sec or Prothrombin Time (PT) >15 sec
- Fibrous tissue in access path
- Participants who cannot tolerate mild sedation
- Pregnancy or lactation
- Patient is unable to comply with requirements of the procedure, i.e. holding breath
- Participation in an investigational trial within 30 days of enrollment
- Participants who are uncooperative or cannot follow instructions
Where in United States
- Johns Hopkins School of MedicineBaltimore, United States
About the trial
What the trial wants to find out
This first-in-human pilot study seeks to evaluate the feasibility and safety of using a percutaneous ultrasound device with needle guide for vascular access. Eligible participants will undergo the procedure of transcatheter arterial chemoembolization for primary or metastatic liver cancer, as part of participants' clinical care. The percutaneous ultrasound device with needle guide will be deployed in eligible participants at the beginning of the procedure for guiding a needle inside the femoral artery. Once the needle is inside the artery, then a guide wire is advanced inside the needle and vascular access is successfully obtained.
Read full original descriptionShow less
The study will identify whether this ultrasound-based device with needle guide is helpful for guiding a needle inside the femoral artery.
The group in the trial
- Device ArmTreatment being tested
Study participants will be enrolled in the Device Arm and the Vu-Path™ Device will be used to access the femoral artery for intra-arterial chemoembolization.
Treatment: Vu-Path™
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 October 2025